Canada approves filgrastim and insulin aspart biosimilars Nypozi and Kirsty

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Canada approves filgrastim and insulin aspart biosimilars Nypozi and Kirsty

Biosimilares/Novedades | Posted 12/11/2021 0 Post your comment

Canada’s drug regulator, Health Canada, has approved the filgrastim and insulin aspart biosimilars Nypozi and Kirsty.

Nypozi is a biosimilar of Amgen’s Neupogen (filgrastim). Filgrastim is a granulocyte colony-stimulating factor (G-CSF). Filgrastim treatment can be used to stimulate the bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy for cancer treatment.

Kirsty is a biosimilar of Novo Nordisk’s NovoLog (insulin aspart). Insulin aspart is a type of manufactured insulin used to treat type 1 and type 2 diabetes. It has a more rapid onset and a shorter duration of activity than normal human insulins.

Nypozi (TX-01) is produced by Taiwan-based biosimilars developer Tanvex BioPharma (Tanvex) and was submitted to Health Canada for approval back in January 2019 [1]. The biosimilar filgrastim was approved on 8 October 2021 as a solution for both intravenous and subcutaneous injection at doses of 300 μg /0.5 mL and 480 μg/0.8 mL.

Kirsty is produced by India-based BioGeneric Pharma (BGP Pharma) The biosimilar insulin aspart was approved by Health Canada on 12 October 2021 as a solution for subcutaneous injection at a dose of 100 units/mL.

There are already two other filgrastim biosimilars and one other insulin aspart biosimilar approved in Canada [2]. BGP Pharma has also received approval in Canada for its adalimumab (Hulio), pegfilgrastim (Fulphila) and trastuzumab (Ogivri) biosimilars [2]. This is Tanvex’s first biosimilar approval in Canada. Tanvex also submitted an application for its proposed filgrastim biosimilar (TX 01) to the US Food and Drug Administration in December 2018 [1]. However, this was rejected in September 2019 [3].

Source: Health Canada, Taipei Times

Related article
Biosimilars of insulin aspart

LATIN AMERICAN FORUM The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View last week’s headline article: Los datos apoyan la intercambiabilidad de los biosimilares de la UE Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de la semana pasada: Los datos apoyan la intercambiabilidad de los biosimilares de la UE Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

References
1. GaBI Online - Generics and Biosimilars Initiative. Tanvex BioPharma submits filgrastim biosimilar to Health Canada [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Nov 12]. Available from: www.gabionline.net/biosimilars/news/Tanvex-BioPharma-submits-filgrastim-biosimilar-to-Health-Canada
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Canada [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Nov 12]. Available from: www.gabionline.net/biosimilars/general/biosimilars-approved-in-canada
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of filgrastim [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Nov 12]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-filgrastim

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.